Phase 2 N=40 Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Overall Response Rate — 37 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=136 PROphylactic Wound VACuum Therapy to Decrease Rates of Cesarean Section in the Obese Population
Wound Complication
Primary: Number of Participants With Wound Complications — 3; 4 Participants
Phase 2 N=24 Aerosol Inhalation Treatment for Dyspnea - Patients
Dyspnea
Primary: Change in Subject Rating of Breathing Discomfort (Dyspnea) Before and After Treatment. — -1.86; -0.61; -0.15 units on a scale — p=0.35
Phase 4 N=33 Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy
Hot Flashes
Primary: Cognitive Function as Assessed by the National Adult Reading Test (NART) — 45.2; 39.6; 42.43; 41.29 units on a scale
Phase 2 N=31 Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)
Atopic Dermatitis
Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) — 70.0; 57.1; 40.0; 28.6 percentage of participants
Phase 4 N=90 Effect of Neuromuscular Blockade on Operating Conditions and Overall Satisfaction During Spinal Surgery
Neuromuscular Blockade · Surgery · Anesthesia
Primary: Mean Value of Peak Inspiratory Pressure — 18.4; 20.2 cmH2O — p=<0.001
N/A N=45 Efficacy of Three Toothpastes Using an in Situ Caries Model
Dental Caries
Primary: Percentage Surface Microhardness Recovery (SMHR) of Phyte (0% 0.425% and 0.85%) at 2 Weeks — 25.53; 26.81; 7.41; 28.88 % SMHR — p=0.7603
N/A N=128 Study in Parkinson's Disease of Exercise
Parkinson Disease
Primary: Percentage of Average Maximum Heart Rate During Exercise as a Measure of Adherence to Exercise — 80.3; 65.9 percentage of maximum heart rate — p=<0.0001
Phase 2 N=192 A Study of MDT-10013 in the Treatment of Acute Postoperative Pain Following Bunionectomy
Postoperative Pain
Primary: Summed Pain Intensity Over 1- 48hrs (SPI-48) From Cohort 1 to 3 — 252.29; 213.28; 191.97; 215.35 units on a scale
Phase 4 N=75 Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)
Hypertension, Pulmonary
Primary: Change From Baseline to Week 24 in the Living With Pulmonary Hypertension (LPH) Questionnaire Total Score — -10.99 Scores
Phase 2 N=109 A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
Papillary Renal Cell Cancer
Primary: Objective Response Rate (RECIST Version 1.1) — 0; 0; 3; 8 Participants
Phase 2 N=42 Dose Dense TC + Pegfilgrastim Support for Breast Cancer
Female Breast Cancer
Primary: Feasibility for Dose-dense TC Therapy: Number of Participants Receiving at Least 90% of Total Dose of Therapy — 37 participants
Phase 2 N=30 Intensity Modulated Radiation Therapy (IMRT) Radiotherapy for Treating Prostate Pelvic Nodes
Prostate Cancer
Primary: Number of Participants Experiencing Expected Toxicities — 13 Participants
Phase 3 N=3,006 Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)
HPV Infections
Primary: Base Study: Combined Incidence of 6-Month Persistent Infection, Cervical Intraepithelial Neoplasia (CIN+), and External Genital Lesions Related to Human Papillomavirus…
Phase 2 N=16 Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission
Lymphoid Leukemia in Remission · Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia
Primary: Probability of Progression-free Survival (PFS) — 52 percentage probability